21 CFR Part 606 · Current Good Manufacturing Practice for Blood and Blood Components

§ 606.110 Plateletpheresis, leukapheresis, and plasmapheresis

Subpart F - Production and Process Controls Official text on eCFR Amendment history

(a) The use of plateletpheresis and leukapheresis procedures to obtain a product for a specific recipient may be at variance with the additional standards for specific products prescribed in this part provided that:

(1) A physician has determined that the recipient must be transfused with the leukocytes or platelets from a specific donor, and

(2) the procedure is performed under the supervision of a responsible physician who is aware of the health status of the donor, and the physician has determined and documented that the donor's health permits plateletpheresis or leukapheresis.

(b) Plasmapheresis of donors who do not meet the donor requirements of §§ 630.10 , 630.15 , 640.64 and 640.65 of this chapter for the collection of plasma containing rare antibodies shall be permitted only with the prior approval of the Director, Center for Biologics Evaluation and Research.

Independent copy, not an official legal edition. 21 CFR is a U.S. Government work in the public domain; this text comes from the eCFR and the annual CFR edition, and may lag recent amendments. The authoritative version is on ecfr.gov. Compliome is not affiliated with or endorsed by FDA. Not legal advice.

What FDA inspectors cite under § 606.110

Form FDA 483 observations citing this section, fiscal years 2012–2018 (Biologics).

  • Center approval for collection of rare antibodies 2
  • Written certification 1
  • Supervision of qualified physician 1

Amendment history

Federal Register documents that created or amended this section.